We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in the Cards for Nektar (NKTR) This Earnings Season?
Read MoreHide Full Article
Nektar Therapeutics (NKTR - Free Report) is scheduled to report fourth-quarter and full-year 2018 results on Feb 28 after market close.
While the company surpassed expectations in two of the last four quarters, it missed the same once and met once, with the average beat being 15.07%.
In the last reported quarter, Nektar reported a positive earnings surprise of 12.5%.
Let’s see how things are shaping up for this announcement.
Factors at Play
Nektar earns revenues from proprietary PEGylation material sales to partners, royalties on sales of partnered drugs like AstraZeneca’s Movantik and Shire’s Adynovate. Royalty revenues displayed an upward trend in the first three quarters of 2018 and the same is likely to continue in the fourth quarter. The Zacks Consensus Estimate for product sales and royalties was $19.35 million.
The company also earns through receipts related to license and collaboration agreements and non-cash royalty revenues. The Zacks Consensus Estimate for collaboration and other revenues is pegged at $2.8 million.
The company also has several candidates in its pipeline, which includes its lead candidate, Onzeald (pain management) and NKTR-214 (an immuno-stimulatory CD122-biased agonist). Nektar has collaborations with multiple drug companies to develop NKTR-214 in combination with their cancer candidates. During the quarter, the company signed a similar agreement with Pfizer (PFE - Free Report) to evaluate NKTR-214 in combination with Bavencio and talazoparib or Xtandi. In September 2018, Nektar initiated a phase III study to evaluate NKTR-214 in combination with Bristol-Myers’ (BMY - Free Report) Opdivo for treating first-line advanced melanoma patients.
Nektar’s analgesic candidate, NKTR-181, is under review with the FDA for treating chronic low back pain in patients new to any opioid therapy. A decision is expected in May this year. The company is in the process of creating a commercialization plan for the drug. We expect the company to provide details on commercialization plans following potential approval of NKTR-181. Investors should focus on any update on late-stage melanoma study on NKTR-214+Opdivo combination therapy and future development plans in other indications.
Earnings Whispers
Our proven model shows that the combination of a positive Earnings ESP and a favorable Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat.
Earnings ESP: Nektar’s Earnings ESP is 0.00%. This is because both the Most Accurate Estimate and the Zacks Consensus Estimate stand at a loss of 70 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Although Nektar’s Zacks Rank #3 increases the predictive power of ESP, its 0.00% ESP makes surprise prediction difficult.
Note that we caution against stocks with a Zacks Rank #4 (Sell) or 5 (Strong Sell) going into an earnings announcement, especially when the company is seeing negative estimate revisions.
A Stock That Warrants a Look
Here is a stock from the pharma space that you may want to consider as our model shows that it has the right combination of elements to post an earnings beat this quarter.
This Could Be the Fastest Way to Grow Wealth in 2019
Research indicates one sector is poised to deliver a crop of the best-performing stocks you'll find anywhere in the market. Breaking news in this space frequently creates quick double- and triple-digit profit opportunities.
These companies are changing the world – and owning their stocks could transform your portfolio in 2019 and beyond. Recent trades from this sector have generated +98%, +119% and +164% gains in as little as 1 month.
Image: Bigstock
What's in the Cards for Nektar (NKTR) This Earnings Season?
Nektar Therapeutics (NKTR - Free Report) is scheduled to report fourth-quarter and full-year 2018 results on Feb 28 after market close.
While the company surpassed expectations in two of the last four quarters, it missed the same once and met once, with the average beat being 15.07%.
In the last reported quarter, Nektar reported a positive earnings surprise of 12.5%.
Let’s see how things are shaping up for this announcement.
Factors at Play
Nektar earns revenues from proprietary PEGylation material sales to partners, royalties on sales of partnered drugs like AstraZeneca’s Movantik and Shire’s Adynovate. Royalty revenues displayed an upward trend in the first three quarters of 2018 and the same is likely to continue in the fourth quarter. The Zacks Consensus Estimate for product sales and royalties was $19.35 million.
The company also earns through receipts related to license and collaboration agreements and non-cash royalty revenues. The Zacks Consensus Estimate for collaboration and other revenues is pegged at $2.8 million.
The company also has several candidates in its pipeline, which includes its lead candidate, Onzeald (pain management) and NKTR-214 (an immuno-stimulatory CD122-biased agonist). Nektar has collaborations with multiple drug companies to develop NKTR-214 in combination with their cancer candidates. During the quarter, the company signed a similar agreement with Pfizer (PFE - Free Report) to evaluate NKTR-214 in combination with Bavencio and talazoparib or Xtandi. In September 2018, Nektar initiated a phase III study to evaluate NKTR-214 in combination with Bristol-Myers’ (BMY - Free Report) Opdivo for treating first-line advanced melanoma patients.
Nektar’s analgesic candidate, NKTR-181, is under review with the FDA for treating chronic low back pain in patients new to any opioid therapy. A decision is expected in May this year. The company is in the process of creating a commercialization plan for the drug. We expect the company to provide details on commercialization plans following potential approval of NKTR-181. Investors should focus on any update on late-stage melanoma study on NKTR-214+Opdivo combination therapy and future development plans in other indications.
Earnings Whispers
Our proven model shows that the combination of a positive Earnings ESP and a favorable Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat.
Earnings ESP: Nektar’s Earnings ESP is 0.00%. This is because both the Most Accurate Estimate and the Zacks Consensus Estimate stand at a loss of 70 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Although Nektar’s Zacks Rank #3 increases the predictive power of ESP, its 0.00% ESP makes surprise prediction difficult.
Note that we caution against stocks with a Zacks Rank #4 (Sell) or 5 (Strong Sell) going into an earnings announcement, especially when the company is seeing negative estimate revisions.
A Stock That Warrants a Look
Here is a stock from the pharma space that you may want to consider as our model shows that it has the right combination of elements to post an earnings beat this quarter.
BioDelivery Sciences International, Inc. has an Earnings ESP of +38.46% and a Zacks Rank #1. The company is scheduled to report results on Mar 14. You can see the complete list of today’s Zacks #1 Rank stocks here.
This Could Be the Fastest Way to Grow Wealth in 2019
Research indicates one sector is poised to deliver a crop of the best-performing stocks you'll find anywhere in the market. Breaking news in this space frequently creates quick double- and triple-digit profit opportunities.
These companies are changing the world – and owning their stocks could transform your portfolio in 2019 and beyond. Recent trades from this sector have generated +98%, +119% and +164% gains in as little as 1 month.
Click here to see these breakthrough stocks now >>